Trial Profile

Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darolutamide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions
Acronyms DAROL
Sponsors Bayer

Most Recent Events

16 Apr 2025 According to a Bayer media release, third interim analysis data will be presented at the upcoming American Urological Association (AUA) Annual Meeting taking place in Las Vegas from April 26-29, 2025.
06 May 2024 Third interim results (at data cut-off: 17 July 2023; n=550) of pre-specified analysis presented at the 119th Annual Meeting of the American Urological Association.
15 Jan 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com